CN109806237A - 一种乳酸环丙沙星泡腾片及其制备方法 - Google Patents
一种乳酸环丙沙星泡腾片及其制备方法 Download PDFInfo
- Publication number
- CN109806237A CN109806237A CN201910184224.5A CN201910184224A CN109806237A CN 109806237 A CN109806237 A CN 109806237A CN 201910184224 A CN201910184224 A CN 201910184224A CN 109806237 A CN109806237 A CN 109806237A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- ciprofloxacin lactate
- effervescent tablet
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229960004055 ciprofloxacin lactate Drugs 0.000 title claims abstract description 12
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000000543 intermediate Substances 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229920001214 Polysorbate 60 Polymers 0.000 abstract 1
- 229920003081 Povidone K 30 Polymers 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种乳酸环丙沙星泡腾片，包括乳酸环丙沙星10‑12份；L‑酒石酸20‑22份；碳酸氢钠20‑22份；羧甲淀粉钠2‑3份；低取代羟丙纤维素2‑3份乳糖30‑33份；聚山梨酯80 2‑3份；聚维酮K30 4‑6份；硬脂酸镁1‑2份。还提供了一种乳酸环丙沙星泡腾片的制备方法，本制备方法制备的产品，为妇科外用产品，药物直达病灶，临床治疗效果好，减小了因服用本产品对机体造成的不良反应。
Description
技术领域
本发明涉及药物制造新技术及药物新的使用新方法领域，具体是一种乳酸环丙沙星泡腾片及其制备方法。
背景技术
阴道炎是阴道粘膜及粘膜下结缔组织的炎症，分为滴虫性阴道炎、霉菌性阴道炎、非特异性阴道炎等，是一种常见的妇科疾病。正常健康妇女，由于解剖学及生物化学特点，阴道对病原体的侵入有自然防御功能，当阴道的自然防御功能遭到破坏，则病原体易于侵入，导致阴道炎症，目前用于妇女阴道炎治疗的药物虽有多品种上市，但仅利用药物本身的有效成份，对感染进行控制，在治疗过程中破坏了阴道内的微生态平衡，使感染得不到根治临床治疗效果不太理想。
发明内容
本发明所要解决的技术问题是提供一种乳酸环丙沙星泡腾片其制备方法，以解决现有技术中存在的缺陷。
本发明解决上述技术问题的技术方案如下：
一种乳酸环丙沙星泡腾片，按重量份包含如下成分:
一种乳酸环丙沙星泡腾片的制备方法，包括如下步骤：
1)将上述物料分别制成酸、碱、主药颗粒，混合均匀；
2)测定中间体含量，确定是否符合要求；
3)将符合要求的中间体压片，然后铝塑、包装。
本发明的有益效果是：本制备方法制备的产品，为妇科外用产品，药物直达病灶，临床治疗效果好，减小了因服用本产品对机体造成的不良反应。
具体实施方式
以下对本发明的原理和特征进行描述，所举实例只用于解释本发明，并非用于限定本发明的范围。
一种乳酸环丙沙星泡腾片，按重量份包含如下成分:
一种乳酸环丙沙星泡腾片的制备方法，包括如下步骤：
1)将上述物料分别制成酸、碱、主药颗粒，混合均匀；
2)测定中间体含量，确定是否符合要求；
3)将符合要求的中间体压片，然后铝塑、包装。
具体实施例1
按照重量份取如下成分：
将上述物料分别制称酸、碱、主药颗粒，混合均匀；测定中间体含量后，压片，进行铝塑包装。
具体实施例2:
按照重量份取如下成分：
将上述物料分别制成酸、碱、主药颗粒，混合均匀；测定中间体含量后，压片，进行铝塑包装。
具体实施例3
按照重量份取如下成分：
将上述物料分别制成酸、碱、主药颗粒，混合均匀；测定中间体含量后，压片，进行铝塑包装。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (2)
1.一种乳酸环丙沙星泡腾片，其特征在于,按重量份包含如下成分:
2.一种乳酸环丙沙星泡腾片的制备方法，其特征在于：包括如下步骤：
1)将上述物料分别制成酸、碱、主药颗粒，混合均匀；
2)测定中间体含量，确定是否符合要求；
3)将符合要求的中间体压片，然后铝塑、包装。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910184224.5A CN109806237A (zh) | 2019-03-13 | 2019-03-13 | 一种乳酸环丙沙星泡腾片及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910184224.5A CN109806237A (zh) | 2019-03-13 | 2019-03-13 | 一种乳酸环丙沙星泡腾片及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109806237A true CN109806237A (zh) | 2019-05-28 |
Family
ID=66608727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910184224.5A Pending CN109806237A (zh) | 2019-03-13 | 2019-03-13 | 一种乳酸环丙沙星泡腾片及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109806237A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR032614A1 (es) * | 2000-03-03 | 2003-11-19 | Ranbaxy Lab Ltd | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina |
| CN104224744A (zh) * | 2014-09-28 | 2014-12-24 | 严相顺 | 用于家蚕细菌病防治的环丙沙星泡腾片 |
-
2019
- 2019-03-13 CN CN201910184224.5A patent/CN109806237A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR032614A1 (es) * | 2000-03-03 | 2003-11-19 | Ranbaxy Lab Ltd | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina |
| CN104224744A (zh) * | 2014-09-28 | 2014-12-24 | 严相顺 | 用于家蚕细菌病防治的环丙沙星泡腾片 |
Non-Patent Citations (4)
| Title |
|---|
| 刘辉等: "盐酸环丙沙星阴道泡腾片的制备与质量控制", 《中国医院药学杂志》 * |
| 李红雨等: "环丙沙星泡腾片治疗细菌性阴道炎临床观察", 《数理医药学杂志》 * |
| 陈勇敢等: "环丙沙星阴道泡腾片的制备及临床应用", 《河南大学学报(医学科学版)》 * |
| 陈洪轩，杜芬英，白颖: "乳酸环丙沙星阴道泡腾片的研制", 《西北药学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101335185B1 (ko) | 활성 주성분 전달용 점막 생체접착성 서방형 담체 | |
| US20070243249A1 (en) | Novel formulation of pyridoxal-5'-phosphate and method of preparation | |
| CN108025014A (zh) | 用于过重女性患者的基于屈螺酮的避孕药 | |
| US20050255157A1 (en) | Sustained release, mucoadhesive vaginal pharmaceutical compositions | |
| JP6479658B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
| EP1972332A1 (en) | Mucosal bioadhesive slow release carrier for delivering active principles | |
| CN107206011B (zh) | 包括雷洛昔芬以及维生素d或其衍生物的复合胶囊 | |
| CN109806237A (zh) | 一种乳酸环丙沙星泡腾片及其制备方法 | |
| JP6469234B2 (ja) | 超速崩壊錠剤及びその製造方法 | |
| NO329663B1 (no) | Anvendelse av en ¿-adrenergisk agonist og en farmasoytisk akseptabel bioadhesiv baerer i produksjon av et medikament | |
| US20230104254A1 (en) | Process for mesalazine solid formulations | |
| KR102431738B1 (ko) | 초고속 붕해 정제 및 그 제조 방법 | |
| AU2001282816A1 (en) | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders | |
| CN101152187A (zh) | 依普利酮药物组合物 | |
| CN102526063A (zh) | 一种含有氯沙坦钾和氢氯噻嗪的复方制剂及其制备方法 | |
| CN112137992A (zh) | 一种用于治疗牙周炎的组合物及其用途 | |
| CN106727579A (zh) | 一种厄贝沙坦/瑞舒伐他汀复方制剂及其制备方法 | |
| NZ571156A (en) | Compressed granulated mucosal bioadhesive slow release carrier for delivering active principles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 1118, langgong Road, Jinshan Industrial Zone, Jinshan District, Shanghai, 201506 Applicant after: Shanghai Huanhua Pharmaceutical Co.,Ltd. Address before: 1118, langgong Road, Jinshan Industrial Zone, Jinshan District, Shanghai, 201506 Applicant before: YOUCARE PHARMACEUTICAL GROUP SHANGHAI PHARMACEUTICAL Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190528 |